GOG-0283
Terminated
Protocol Information
A Phase II Trial of DCTD-Sponsored Dasatinib (NSC #732517 IND# 120636) in Recurrent/Persistent Ovary, Fallopian Tube, Primary Peritoneal, and Endometrial Clear Cell Carcinoma Characterized for the Retention or Loss of BAF250a Expression
Principal Investigator
David Hyman
Status
Terminated
Open to Accrual
February 3, 2014
Temporarily Closed to Accrual
February 3, 2014
Temporarily Closed to Accrual
December 19, 2014
Open to Accrual
December 19, 2014
Open to Accrual
November 9, 2015
Temporarily Closed to Accrual
August 1, 2016
Temporarily Closed to Accrual
August 10, 2016
Closed to Accrual
March 16, 2017
Closed to Accrual & Treatment
November 11, 2016
Terminated
June 26, 2023
Disease Site
Gynecologic [GY] Ovarian
Phase
II
Developmental Therapeutics
No
Primary Objective
To assess the clinical activity of dasatinib in patients with recurrent or persistent ovarian, fallopian tube, primary peritoneal, and endometrial clear cell carcinoma using objective tumor response (complete and partial):
– in patients without loss of BAF250a expression, and
– in patients with loss of BAF250a expression
Patient Population
Patients with recurrent or persistent ovarian, fallopian tube, primary peritoneal, and endometrial clear cell carcinoma.
Target Accrual
62
Patient Study Webpage
-
Share this study.
-
-
-
-
